Lymphatic Filariasis
Conditions
Keywords
Wuchereria bancrofti, Anopheles, Albendazole, Ivermectin, MDA
Brief summary
Lymphatic filariasis is a public health problem in Mali. The existing data are not up to date and most of them are more than 15 years old. To address this issue in April 2000, the investigators started studies to update the epidemiology of lymphatic filariasis. There is no ongoing lymphatic filariasis control program in 2000 in Mali in terms of preventive chemotherapy treatment or vector control. To fill these gaps, this current study aims to assess the impact of albendazole-ivermectin combination treatment on Wuchereria bancrofti infection and transmission in 6 rural highly endemic villages of Mali.
Detailed description
Lymphatic filariasis is a public health problem in Mali. The existing data are not up to date and most of them are more than 15 years old. To address this issue in April 2000, the investigators started studies to update the epidemiology of lymphatic filariasis. As a result, in two rural areas (Banambani and Sirakoro) located at about 25 km North-East Bamako, the parasite prevalence using ICT cards in August 2000 were 16% (n=150) and 15.0% (n=113) respectively in Banambani and Sirakoro. There is no ongoing lymphatic filariasis control program in 2000 in Mali in terms of preventive chemotherapy treatment or vector control. To fill these gaps, this current study aims to assess the impact of albendazole-ivermectin combination treatment on Wuchereria bancrofti infection and transmission in 6 rural highly endemic villages of Mali. The study will be conducted in three phases: the pre treatment assessment of lymphatic filariasis infection and transmission parameters, treatment phase with annual single dose of albendazole and ivermectin and the post treatment assessment of Anopheles gambiae s.l mosquitoes, the transmission parameters of the vectors in the community, human infection prevalence post treatment using Giemsa -stained thick smears and others test like the Immuno chromatographic test (ICT).
Interventions
DRUG''albendazole'' and ''ivermectin''
annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)
Sponsors
Malaria Research and Training Center, Bamako, Mali
World Health Organization
Centre d'Appui à la lutte contre la Maladie
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* resident of the 6 villages * 5 years and above
Exclusion criteria
* pregnant women * breastfeeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| vector infection and infectivity rates | up to 7 months | vectors are collected with human landing catch technique and the presence of Wb larvae stage s assessed using dissection method |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Post MDA adverses events related to the drug albendazo and ivermectin | up to 12 months | after the administration of the drug the investigators assess the reaction to the treatment |
| impact of albendazole ivermectin treatment on microfilaremia | up to 12 months | night thick smears on eligible volunteers 5 years and above |
Outcome results
None listed